Cargando…
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
Neuroblastoma (NB) is one of the most common solid tumors in childhood. To date, targeting MYCN, a well-established driver gene in high-risk neuroblastoma, is still challenging. In recent years, inhibition of bromodomain and extra terminal (BET) proteins shows great potential in multiple of Myc-driv...
Autores principales: | Li, Zhiheng, Lim, Su Lin, Tao, Yanfang, Li, Xiaolu, Xie, Yi, Yang, Chun, Zhang, Zimu, Jiang, You, Zhang, Xianbing, Cao, Xu, Wang, Hairong, Qian, Guanghui, Wu, Yi, Li, Mei, Fang, Fang, Liu, Ying, Fu, Mingcui, Ding, Xin, Zhu, Zhenghong, Lv, Haitao, Lu, Jun, Xiao, Sheng, Hu, Shaoyan, Pan, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726414/ https://www.ncbi.nlm.nih.gov/pubmed/33324552 http://dx.doi.org/10.3389/fonc.2020.574525 |
Ejemplares similares
-
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
por: Wu, Shuiyan, et al.
Publicado: (2021) -
ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways
por: Liao, Xinmei, et al.
Publicado: (2021) -
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
por: Zhang, Kunlong, et al.
Publicado: (2022) -
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
por: Ma, Li, et al.
Publicado: (2022) -
ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma
por: He, Ling, et al.
Publicado: (2020)